Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
Explore the impact of the first-line application of Pembrolizumab with or without Lenvatinib or chemotherapy, on the survival, disease progression, and drug safety of patients with advanced biliary tract cancers
Epistemonikos ID: ee47db5ff7a03be4fc61e9678afa0609a0ce6262
First added on: May 15, 2024